In a resounding affirmation of her leadership in clinical research and health innovation, a Nigerian born, Canadian citizen, Olufunke Omotayo, a Nigerian-born Canadian citizen, has been appointed as Local Trial Manager (Country Study Manager) for Amgen Inc. in Canada, a strategic appointment that, according to industry observers, marks a significant advancement in the evolution of biopharmaceutical trial oversight.

Operating at the intersection of science, strategy, and societal impact, Omotayo assumes her new position with a reputation that precedes her. Known for transforming complex research landscapes into streamlined, patient-centered trial ecosystems, her appointment at Amgen, a global leader in biotechnology, reverberates far beyond corporate boardrooms and clinical corridors.

Amgen, headquartered in California, has long been at the forefront of developing therapies for grievous conditions such as cancer, cardiovascular, and autoimmune diseases. The company’s commitment to scientific excellence and medical innovation demands leadership that not only understands protocol but embodies progress. Omotayo’s arrival is seen as a seamless match.

“Olufunke is more than a clinical operations expert; she’s a visionary strategist with a pulse on the future of health systems,” said a senior colleague familiar with the appointment. “Her leadership will not only uphold Amgen’s global standards but elevate Canada’s role in the next generation of clinical breakthroughs.”

As Country Study Manager, Omotayo is tasked with overseeing the full lifecycle of clinical trials at the national level from initial Country Operational Landscape Assessments (COLA) through site activation and patient recruitment, to the final study close-out and archiving. Her work will ensure that every step of the process adheres to international regulatory standards (ICH-GCP) while remaining attuned to the specific needs of the Canadian healthcare environment.

But Omotayo’s impact is not confined to compliance and coordination. Her career has been defined by a rare duality: technical mastery balanced with a deeply ethical, human-centered approach. In her previous decade-long tenure at Alberta Health Services, she wore many hats from clinical trial consultant to health advisory council leader each marked by strategic foresight and unwavering commitment to public health.

In her new role at Amgen, Omotayo also leads stakeholder collaboration across global and local levels, building partnerships that bridge research intent with patient reality. She has the authority to guide country-specific study decisions, ensuring localized insights are never lost in global templates.

“She has an innate ability to turn data into direction,” said a peer from her Alberta Health days. “Whether she’s refining protocols or speaking with patients, she makes every detail count—because to her, every patient counts.”

A Doctor of Pharmacy with advanced degrees in public health and business administration, Omotayo’s credentials reflect a rare interdisciplinary fluency. Her portfolio of certifications, ranging from AWS cloud architecture to project management and agile methodologies, is more than a testament to her adaptability; it’s proof that she’s writing the rulebook for 21st-century health leadership.

Her therapeutic expertise spans oncology, hematology, infectious diseases, and neurology, making her uniquely equipped to manage Amgen’s diverse clinical portfolio. Her ability to synthesize scientific data, logistical frameworks, and human insight into cohesive trial strategies makes her an indispensable asset to the global medical community.

Beyond the resume, what truly distinguishes Omotayo is her ethos. In every role, she has championed inclusivity, innovation, and integrity. Her efforts in establishing health advisory councils across Northern Alberta ensured that underrepresented communities had a voice in policy. Her earlier public health campaigns promoted equity in preventive care long before it became a sector buzzword.

In a moment when the stakes of medical research have never been higher, Amgen’s appointment of Olufunke Omotayo is more than a personnel move, it’s a statement of intent. A declaration that the future of healthcare belongs to those who lead with both rigor and empathy.

As she steps into this new chapter, all eyes will be on Omotayo not simply to manage trials, but to redefine what success looks like in global clinical research.